Novo Nordisk Partners With OpenAI to Accelerate the Next Wave of Obesity Drugs
Summary
The maker of Ozempic and Wegovy is embedding OpenAI’s technology across its entire operation — from drug target discovery to clinical trial design to manufacturing — as it races to claw back market share from Eli Lilly in the fiercely competitive obesity drug market.
Novo Nordisk A/S announced on April 14, 2026, that it will integrate OpenAI’s artificial intelligence across the company to speed up drug development, according to a report by Bloomberg. Financial terms of the deal were not disclosed.
The partnership goes beyond the bespoke ChatGPT access Novo employees already had. Pilot programs will launch across the drugmaker’s research and development, manufacturing, and commercial operations units, with full integration planned by the end of this year. The aim is to help Novo identify drug targets faster, design better clinical trials, and extract clearer insights from the company’s internal datasets.
Novo CEO Mike Doustdar framed the initiative as augmentation rather than automation, stating that the deal is about supercharging scientists, not replacing them. He compared the transformation to the shift from fax machines to email — a fundamental upgrade in how work gets done rather than a reduction in who does it.
The urgency is competitive. Novo pioneered the current generation of GLP-1 obesity drugs with Ozempic and Wegovy but has lost market share to U.S. rival Eli Lilly, whose competing treatments have gained ground. Doustdar, who took over as CEO in August, has already cut approximately 9,000 jobs and pushed for faster decision-making across the organization. The OpenAI integration fits that broader restructuring: compressing timelines in a drug development process that traditionally spans years.
The deal adds to Novo’s growing AI infrastructure, which includes a research-focused partnership with Nvidia announced last year. Together, these agreements position Novo as one of the most AI-aggressive pharmaceutical companies in the industry.
Whether AI can meaningfully shorten drug development cycles remains an open question — regulatory timelines and clinical trial requirements impose hard floors on speed regardless of how fast targets are identified. But for Novo, the bet is clear: in a market where being second to market already cost it its lead, any acceleration in the pipeline carries outsized strategic value.